Interview: An architectural journey: from trees, dendrons/dendrimers to nanomedicine. Interview by Hannah Stanwix

Nanomedicine (Lond). 2012 Jul;7(7):953-6. doi: 10.2217/nnm.12.81.

Abstract

Donald Tomalia received his Bachelor of Arts degree in Chemistry from the University of Michigan (MI, USA). He received his PhD in physical-organic Chemistry from Michigan State University (MI, USA) in 1968 while working at The Dow Chemical Company (MI, USA). In 1990 he moved to Michigan Molecular Institute (MI, USA) as Professor and Director of Nanoscale Chemistry and Architecture. He has subsequently founded three dendrimer based-nanotechnology companies, Dendritech, Inc. (MI, USA), Dendritic Nanotechnologies, Inc. (MI, USA) and NanoSynthons LLC (MI, USA). Donald Tomalia is currently Director of the National Dendrimer & Nanotechnology Center (MI, USA), CEO/founder of NanoSynthons LLC (MI, USA), distinguished visiting Professor, Columbia University (NY, USA) and affiliate Professor, Department of Physics, Virginia Commonwealth University (VA, USA). He is best known for his discovery of dendrimers and has received several awards for his accomplishments and contributions to science, including the 2012 Wallace H Carothers Award. He has authored over 250 publications, as well as over 128 patents.

Publication types

  • Interview

MeSH terms

  • Dendrimers / chemistry
  • Dendrimers / therapeutic use*
  • Drug Delivery Systems / methods
  • Humans
  • Nanomedicine* / methods
  • Nanotechnology / methods

Substances

  • Dendrimers